Literature DB >> 1908435

Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants.

A J George1, H M McBride, M J Glennie, L J Smith, F K Stevenson.   

Abstract

Anti-idiotypic antibodies can be used as probes to distinguish neoplastic cells from their normal counterparts. In addition they have been used in the passive therapy of B cell tumors. In this report we describe a panel of 7 rat monoclonal antibodies raised against idiotypic determinants carried by the IgM molecule of the BCL1 lymphoma. The majority (6/7) of these antibodies recognize private idiotypic determinants that are carried on the isolated mu heavy chain of the molecule, and do not require the lambda chain for reactivity. This is unusual for antibodies raised against the idiotype of the whole immunoglobulin molecule, which normally require both chains for reactivity. The antibodies do not, however, bind peptides corresponding to the complementarity determining regions of the mu heavy chain of BCL1. The antibodies perform well in complement mediated cytotoxicity, and, in at least one case, are effective in the passive immunotherapy of BCL1 lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908435     DOI: 10.1089/hyb.1991.10.219

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  2 in total

1.  Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.

Authors:  Emily L Williams; Stuart N Dunn; Sonya James; Peter W Johnson; Mark S Cragg; Martin J Glennie; Juliet C Gray
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531

2.  Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Authors:  Anna H Turaj; Khiyam Hussain; Kerry L Cox; Matthew J J Rose-Zerilli; James Testa; Lekh N Dahal; H T Claude Chan; Sonya James; Vikki L Field; Matthew J Carter; Hyung J Kim; Jonathan J West; Lawrence J Thomas; Li-Zhen He; Tibor Keler; Peter W M Johnson; Aymen Al-Shamkhani; Stephen M Thirdborough; Stephen A Beers; Mark S Cragg; Martin J Glennie; Sean H Lim
Journal:  Cancer Cell       Date:  2017-11-30       Impact factor: 31.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.